FDA grants Priority Review for AstraZeneca's Calquence in untreated mantle cell lymphoma.
AstraZeneca's blood cancer drug, Calquence (acalabrutinib), has received Priority Review from the FDA for treating adults with untreated mantle cell lymphoma (MCL). The FDA's decision is expected by early 2025. Clinical trials showed Calquence, combined with bendamustine and rituximab, reduced disease progression or death by 27% compared to standard chemotherapy. Calquence is already approved for MCL patients after prior therapy.
October 03, 2024
9 Articles